Venrock Healthcare Capital Partners III, L.P. 4

What Happened
Venrock Healthcare Capital Partners III, L.P. (a reported 10% owner) sold a total of 214,631 KalVista (KALV) shares in multiple transactions on March 25–26, 2026, disposing of roughly $3.69 million of stock. Transactions listed: 174,485 shares at a weighted avg $16.95 ($2.96M), 160 shares at $17.53 ($2.8K), 21,386 shares at $17.76 ($379.8K), 15,417 shares at $18.82 ($290.1K), and 3,183 shares at $19.12 (~$60.9K). These were reported as sales (code S) and described as open-market or private sales.

Key Details

• Transaction dates: March 25–26, 2026; Form 4 filed March 27, 2026 (filed within the standard 2-business-day window).
• Prices: reported as weighted averages; underlying per-share price ranges disclosed in footnotes (rough ranges $16.51–$19.25 across transactions). Full per-price breakdown available upon request as noted in the filing.
• Shares sold: 214,631; approximate proceeds: $3,691,148.
• Shares owned after transaction: Venrock-affiliated entities together own roughly 5.09–5.13 million KALV shares across VHCP3, VHCP Co-3 and VHCP EG; VHCP3 alone holds ~1.10 million shares (see filing footnotes for exact per-entity totals).
• Footnotes: multiple weighted-average price footnotes (F1, F4–F6, F8–F10) cover price ranges; ownership breakdown and manager disclaimers given (VHCPM3/VHCPMEG and named voting members disclaim direct beneficial ownership except for indirect pecuniary interest).
• Filing timeliness: No late filing indicated.

Context
This is institutional selling by a 10% investor (Venrock) rather than an individual officer or director. Sales like these can be routine portfolio rebalancing or liquidity actions and do not by themselves indicate management sentiment about the company’s operations. The filing provides weighted-average prices and offers to supply the per-transaction price breakdown on request for investors who want more granular detail.